PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(...( - Data Featured in Panel Discussio...),Health

- Data Featured in Panel Discussion and Presented in Poster Session at American Academy of Facial Plastic and Reconstructive Surgery Annual Fall

Meeting -

PALO ALTO, Calif. and CHICAGO, Sept. 18 /PRNewswire/ -- PEAK Surgical, Inc., a medical device company that has developed a new tissue dissection system based on a proprietary technology, announced preclinical study results showing that its PEAK PlasmaBlade(TM) Needle cuts tissue with significantly reduced thermal tissue injury compared to traditional electrosurgery and significantly less bleeding than that produced by a standard scalpel.

"Traditional electrosurgical instruments produce a zone of thermal injury to surrounding tissue, which can limit their use in facial surgery," said lead study investigator Dr. Gregory S. Keller, co-director of the Facial Plastic Surgery Fellowship at the University of California, Los Angeles Medical School and clinical associate professor of surgery at UCLA. "The findings of this comparative preclinical study demonstrate that the PlasmaBlade Needle causes less thermal tissue damage than traditional electrosurgery because it cuts and coagulates at a much lower temperature and delivers less heat. Reducing collateral tissue damage is important for improved surgical incision wound healing. The PlasmaBlade Needle may be an important surgical tool for facial tissue dissection in plastic and reconstructive surgery."

Dr. Keller presented the study results today in a poster session at the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) Annual Fall Meeting in Chicago. The data also will be featured in a panel discussion, titled "Minimally Invasive vs Maximally Effective Treatments: The Role of Office-Based Procedures in Facial Plastic Surgery," on Saturday, September 20, in which Dr. Keller will participate.

The PlasmaBlade Needle, which has been cleared for use by the U.S. Food and Drug Administrat
'/>"/>